# Does NJ Medicaid Cover Zepbound or Wegovy? NJ FamilyCare's GLP-1 Rules By Nora Bissett, Pricing Editor (https://glpwatchdog.org/authors/nora-bissett) | Published: 2026-11-06 Canonical page: https://glpwatchdog.org/research/new-jersey-medicaid-glp1-coverage > New Jersey's Medicaid rule bars obesity drugs, yet NJ FamilyCare pays for Zepbound when sleep apnea is diagnosed and for Wegovy in heart disease or MASH. The protocol criteria, the orlistat exception, what full coverage would cost the state, and how to appeal. ## Key points - Weight loss alone is excluded by state rule; orlistat is the one obesity drug that stays covered. - Wegovy is covered for heart disease at a BMI of 27 or more, with a cardiologist, vascular specialist or endocrinologist involved. - Wegovy for MASH needs documented F2 or F3 fibrosis, no cirrhosis and a liver, GI or hormone specialist. - Zepbound is covered for sleep apnea; one plan sets the bar at AHI 15 and BMI 30, with no CPAP step. - The state estimated full coverage at $208.3 million in gross yearly spending and has not adopted it. Not for weight loss. As of November 2026, NJ FamilyCare, New Jersey’s Medicaid program, does not pay for Zepbound or Wegovy to treat obesity, but it pays for Wegovy in heart disease and Zepbound in sleep apnea, each when the clinical criteria are met.[1][5] Wegovy also has a route for the liver disease MASH, and children can get a weight drug case by case under federal child-health rules.[1][2] > **About this article.** This page reads New Jersey’s drug rule, the Wegovy protocol its Drug Utilization Review Board adopted in October 2025, the board’s October 2026 packet, and a Department of Human Services memo to the Legislature, as they stood on November 6, 2026. The state’s own Zepbound protocol text is not posted, so the sleep apnea criteria below come from one NJ FamilyCare plan’s policy, and we could not open the NJ FamilyCare member site. To compare states, use the [state Medicaid GLP-1 checker](https://glpwatchdog.org/tools/state-medicaid-glp1-checker). ## Does NJ FamilyCare cover Zepbound or Wegovy for weight loss? No. New Jersey’s pharmacy rule lists “antiobesics and anorexiants” used to treat obesity among the drugs it does not cover.[5] One NJ FamilyCare plan’s Zepbound policy puts it plainly: weight loss alone is “an excluded benefit.”[6] This is legal under federal law. Drugs used for weight loss are on the short list of medicines a state Medicaid program may leave out.[10] Our explainer on [how Medicaid splits Ozempic from Wegovy](https://glpwatchdog.org/research/does-medicaid-cover-ozempic-and-wegovy) walks through that federal option, and the [Medicaid coverage hub](https://glpwatchdog.org/insurance/medicaid) shows how other programs use it. The rule has one carve-out inside it. Lipase inhibitors, the class that holds orlistat (Xenical), stay covered once BMI reaches 30, or from 27 up to 30 when the person also has high blood pressure, diabetes or abnormal cholesterol.[5] No GLP-1 belongs to that class, so the exception does not reach Wegovy or Zepbound. ## When will New Jersey Medicaid pay for a GLP-1? When the prescription is for a use on the FDA label other than weight loss. The Department of Human Services told the Legislature that NJ FamilyCare “already provides coverage” in those cases, naming Wegovy for heart disease and Zepbound for sleep apnea.[1] The review board’s own indication table, updated in June 2026, lines the drugs up the same way and adds Wegovy for MASH.[4] *NJ FamilyCare GLP-1 routes by use, from state documents read November 6, 2026* | Use | Drug | Main requirements | Source | | --- | --- | --- | --- | | Weight loss alone | Wegovy, Zepbound | Not covered | N.J.A.C. 10:51-1.13 | | Type 2 diabetes | Ozempic, Mounjaro, Trulicity, Rybelsus, Victoza and others | Board protocol; a metformin trial still applies | DURB minutes, October 2025 | | Lowering heart attack and stroke risk | Wegovy | Established heart or artery disease; BMI of 27 or more; cardiologist, vascular specialist or endocrinologist | Wegovy protocol, October 2025 | | MASH with F2 to F3 fibrosis | Wegovy | Documented fibrosis stage; no cirrhosis; liver specialist, GI doctor or endocrinologist | Wegovy protocol, October 2025 | | Moderate to severe sleep apnea | Zepbound | Adult with obesity; one plan sets the bar at AHI 15 and BMI 30 | DHS memo; plan policy | | Children, weight | Case by case | Medical necessity under EPSDT | DHS memo | ## What does the Wegovy protocol require for heart disease? Proof of heart or artery disease that already exists, plus a BMI at or above 27.[2] The protocol accepts any one of six kinds of evidence: a past heart attack; a past stroke or mini-stroke; leg artery disease with symptoms, shown by an ankle-brachial index under 0.85, an artery procedure or an amputation; a positive nuclear stress test; ischemic cardiomyopathy; or a past bypass, stent or angioplasty.[2] That is a wider list than many states use, and it tracks the label, which covers adults with established heart disease and either obesity or overweight.[12] The rest of the file is practical. A cardiologist, vascular specialist or endocrinologist must prescribe or consult, the patient stays on heart medicines, and the chart shows lifestyle counseling and no second GLP-1.[2] The protocol does not rule out type 2 diabetes; it only says the drug should be used “with caution” in type 1.[2] The board approved this version in October 2025, and the commissioners signed off on it by April 2026.[2][3] ## Does NJ FamilyCare cover Wegovy for fatty liver disease? Yes, for MASH with moderate to advanced scarring. The request needs documented fibrosis at stage F2 or F3, notes or labs showing no cirrhosis, and a hepatologist, gastroenterologist or endocrinologist as prescriber or consultant.[2] The FDA approved this use on an accelerated basis, pending a confirmatory trial.[12] Our page on [semaglutide and MASH](https://glpwatchdog.org/research/glp1-and-fatty-liver-mash) covers what that approval rests on. Renewal works the same way for both Wegovy routes: no sign that the disease has progressed, continued lifestyle changes, and either the 2.4 mg weekly maintenance dose or a written reason for a different one.[2] Heart patients must also still be on their heart medicines.[2] ## What do plans ask for before covering Zepbound for sleep apnea? The state board recommended a Zepbound protocol in April 2025, and the commissioners signed off on that meeting’s protocols that summer, but the protocol text is not on the board’s site.[2] The clearest posted version is Aetna Better Health of New Jersey’s policy, effective May 1, 2025.[6] It asks for an adult with obesity whose current BMI is at least 30, and moderate to severe sleep apnea, meaning 15 or more breathing events an hour on a lab study or a home sleep test.[6] It sets no CPAP trial, which keeps it close to the label: Zepbound’s sleep apnea use covers adults with obesity and names no device step.[11] The first approval lasts six months; renewal for 12 months needs fewer sleep apnea symptoms and a maintenance dose of 10 or 15 mg.[6] Treat those details as one plan’s reading until your own plan confirms them. Most NJ FamilyCare drug spending runs through the managed care plans rather than the state’s fee-for-service program: in the second quarter of 2026 the plans logged 69,409 GLP-1 claims against 419 in fee-for-service.[4] Our guide to [Zepbound for sleep apnea](https://glpwatchdog.org/research/zepbound-for-sleep-apnea) explains the trials behind the indication. ## Why doesn’t New Jersey cover weight-loss drugs? Cost, mainly. The state’s fiscal 2026 budget asked the department to study full coverage, and its memo put a price on it. Actuaries estimated $37.5 million in gross spending on weight-loss drugs under current policy and $208.3 million under full coverage, a $170.8 million increase before rebates.[1] After rebates and the federal match, the state’s own share would rise from $7.5 million to $45.2 million.[1] The memo called those figures best guesses made in August 2025 and pointed to federal Medicaid cuts expected to bite from fiscal 2027 as a reason for caution.[1] It reported that coverage would be simple to run but did not recommend it.[1] A bill filed in the Assembly in January 2026, A3369, would require Medicaid and NJ FamilyCare to cover anti-obesity medications; as of November 6, 2026, the Legislature’s record shows only its referral to the Assembly Health Committee.[15] Nothing we read shows the state adopting full coverage. Next door, [Pennsylvania’s Medicaid GLP-1 rules](https://glpwatchdog.org/research/pennsylvania-medicaid-glp1-coverage) make a useful comparison. ## Can a child on NJ FamilyCare get a GLP-1 for weight? Possibly. The department’s memo says federal EPSDT rules require weight-loss drug coverage for children “in certain cases.”[1] Wegovy is approved for obesity from age 12.[12] We found no published pediatric protocol, so the request goes through a medical necessity review. Families should ask for that review by name and attach growth charts and records of what has been tried. ## How do you appeal a GLP-1 denial in New Jersey? Check who sent the denial. Plan members, which is most of NJ FamilyCare, appeal to the plan first: federal rules give 60 calendar days from the notice, and the appeal can be filed by phone or in writing.[8] If the plan upholds the denial, a state fair hearing request is due within the window on the plan’s notice, which federal rules set at 90 to 120 days.[9] An urgent appeal must be decided within 72 hours.[9] For the smaller fee-for-service group, the state rule allows only 20 days from the notice to request a hearing.[7] Either way, a denial for missing records, such as no sleep study or no fibrosis stage, is usually fixed faster by resubmitting than by appealing. Our walkthrough of [prior authorization and appeals](https://glpwatchdog.org/research/glp1-prior-authorization-and-appeals) covers what a strong file contains. ## What are the options if NJ FamilyCare says no? Paying cash, without the manufacturer copay card: Lilly’s card terms exclude anyone enrolled in Medicaid.[13] In the prices we track, Novo Nordisk sells most Wegovy pen doses for $349 a month, and Lilly’s Zepbound KwikPen costs $299 at the starting dose, $399 at 5 mg and $449 at higher doses refilled on time.[13][14] Our list of the [cheapest ways to get a GLP-1 without insurance](https://glpwatchdog.org/research/cheapest-glp1-without-insurance) compares the routes. ## Frequently asked questions ### Does NJ Medicaid cover Zepbound? Only for sleep apnea. As of November 2026, New Jersey's Department of Human Services says NJ FamilyCare covers Zepbound for sleep apnea but not for weight loss. One plan's policy wants an adult whose BMI is 30 or higher and whose sleep study counts 15 or more breathing events an hour. ### Does NJ FamilyCare cover Wegovy? For heart disease and MASH, not for weight loss. The state's Wegovy protocol covers adults who already have heart disease and a BMI at or above 27, and adults with MASH and F2 to F3 liver fibrosis, each with a specialist prescribing or consulting. ### Does New Jersey Medicaid cover Ozempic? Yes, for type 2 diabetes, through a review board protocol that still asks for a metformin trial. Ozempic is not covered when it is prescribed for weight loss. ### Will New Jersey Medicaid start covering weight-loss drugs? Not as of November 2026. The state studied full coverage for its 2026 budget and estimated it would raise gross spending from $37.5 million to $208.3 million a year. The memo did not recommend a change. A 2026 Assembly bill, A3369, would require coverage but had not left committee, and no new coverage rule had been adopted. ### Does NJ Medicaid cover any weight-loss medication? Orlistat. New Jersey's rule keeps lipase inhibitors covered once BMI reaches 30, or from 27 to 30 alongside high blood pressure, diabetes or abnormal cholesterol. Other obesity drugs are excluded. ### How long do I have to appeal an NJ FamilyCare denial? If a health plan denied it, federal rules give 60 days from the notice to appeal to the plan, then 90 to 120 days after the plan's decision to ask for a state fair hearing. For fee-for-service members, New Jersey's rule allows 20 days from the notice. ## References 1. New Jersey Department of Human Services NJ FamilyCare Coverage of Weight Loss Drugs (memo to the Legislature, SFY 2026). nj.gov. 2025. https://www.nj.gov/humanservices/dmahs/documents/news/GLP1_Memo.pdf 2. New Jersey Drug Utilization Review Board Meeting packet, October 22, 2025, including the Addendum to Protocol for Wegovy (MACE and MASH). nj.gov. 2025. https://www.nj.gov/humanservices/dmahs/documents/boards/durb/meeting/DURB_meeting_packet_for_Oct-2025.pdf 3. New Jersey Drug Utilization Review Board Meeting summary, April 15, 2026. nj.gov. 2026. https://www.nj.gov/humanservices/dmahs/documents/boards/durb/meeting/DURB_Meeting_Summary_4-15-26.pdf 4. New Jersey Drug Utilization Review Board Agenda packet, October 21, 2026: GLP-1 utilization, 2024 Q1 to 2026 Q2. nj.gov. 2026. https://nj.gov/humanservices/dmahs/documents/boards/durb/meeting/Agenda%20Packet_NJDURB%20October%202026.pdf 5. State of New Jersey N.J.A.C. 10:51-1.13: Non-covered pharmaceutical services. Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/regulations/new-jersey/N-J-A-C-10-51-1-13 6. Aetna Better Health of New Jersey Coverage policy: Zepbound OSA (tirzepatide), effective May 1, 2025. aetnabetterhealth.com. 2025. https://ch.aetnabetterhealth.com/content/dam/aetna/medicaid/pdfs/formulary/guidelines/Zepbound-OSA-Aetna-NJ-Medicaid-Policy-ua.pdf 7. State of New Jersey N.J.A.C. 10:49-10.3: Fair hearings. Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/regulations/new-jersey/N-J-A-C-10-49-10-3 8. Code of Federal Regulations 42 CFR §438.402: General requirements (managed care grievances and appeals). Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/cfr/text/42/438.402 9. Code of Federal Regulations 42 CFR §438.408: Resolution and notification of grievances and appeals. Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/cfr/text/42/438.408 10. United States Code 42 U.S.C. §1396r-8: Payment for covered outpatient drugs (Social Security Act §1927). Legal Information Institute, Cornell Law School. 2026. https://www.law.cornell.edu/uscode/text/42/1396r-8 11. Eli Lilly and Company ZEPBOUND (tirzepatide) injection: prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b 12. Novo Nordisk WEGOVY (semaglutide) injection and tablets: prescribing information. DailyMed. 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b 13. Eli Lilly and Company Zepbound savings and self-pay options, with card terms. zepbound.lilly.com. 2026. https://zepbound.lilly.com/savings 14. Novo Nordisk Wegovy savings offer. novocare.com. 2026. https://www.novocare.com/obesity/products/wegovy/savings-offer.html 15. New Jersey Legislature Assembly No. 3369 (2026-2027 session): requires SHBP, SEHBP, Medicaid and NJ FamilyCare to cover anti-obesity medications. njleg.gov. 2026. https://pub.njleg.gov/Bills/2026/A3500/3369_I1.HTM --- Cite as: GLP Watchdog, Nora Bissett, "Does NJ Medicaid Cover Zepbound or Wegovy? NJ FamilyCare's GLP-1 Rules", published 2026-11-06. https://glpwatchdog.org/research/new-jersey-medicaid-glp1-coverage Canonical HTML page: https://glpwatchdog.org/research/new-jersey-medicaid-glp1-coverage Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.